Benjamin Kelmendi

Ben is the Co-Director of the Yale Program for Psychedelic Science and an Assistant Professor of Psychiatry at the Yale School of Medicine, one of the top-ranked psychiatry programs worldwide. He was the Principal Investigator on the first double-blind clinical trial investigating psilocybin in the treatment of OCD, and demonstrated early efficacy for esketamine. In 2021, Ben was the first recipient of a federal grant for clinical psychedelic research since 1967.‍